HC Wainwright & Co. Reiterates Buy on Biora Therapeutics, Maintains $65 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Biora Therapeutics (NASDAQ:BIOR) and maintained a $65 price target.
July 27, 2023 | 4:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biora Therapeutics' stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $65 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and a maintained price target of $65 by HC Wainwright & Co. suggests a positive outlook for Biora Therapeutics, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100